Lanreotide diTFA, a cutting-edge biomedicine of novel nature, is deployed in the intricate realm of acromegaly, an enigmatic hormonal disorder marked by the unwarranted surge in growth hormone secretion. Through virtue of embodying the essence of a somatostatin analog, this wonder drug efficaciously curbs the exocrine release of growth hormone, thus serving as a catalyst in abating the diverse array of notabilities accompanying acromegaly.
CAT# | R2026 |
CAS | 1024499-83-9 |
M.F/Formula | C58H71F6N11O14S2 |
M.W/Mr. | 1324.37 |
* Please kindly note that our products and services can only be used to support research purposes (Not for clinical use).
Creative Peptides has accumulated a huge library of peptide knowledge including frontier peptide articles, application of peptides, useful tools, and more!
GR 94800, is a linear heptapeptide with the structure of PhCO-Ala-Ala-D-Trp-Phe-D-Pro-Nle Amide, which is a high ...
Eledoisin is an undecapeptite of mollusk origin, which was first separated from posterior salivary glands of two ...
PR 39, a porcine 39-aa peptide antibiotic, was originally isolated from the upper part of the small intestine o ...
Fertirelin acetate, classified into peptide hormone, is a gonadotropin-releasing hormone (GnRH) antagonist or ...
The immunomodulator mifamurtide (liposomal muramyltripeptide phosphatidyl ethanolamine [L-MTP-PE]) is a syntheti ...